Last Updated : February 20, 2025
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
pasireotide (Signifor LAR)
Therapeutic Area: Acromegaly, adults
Draft recommendations posted for stakeholder feedback: March 20, 2025
End of feedback period: April 3, 2025
Draft Recommendation
ferric carboxymaltose (Ferinject)
Therapeutic Area: Iron deficiency in adult patients with heart failure
Draft recommendations posted for stakeholder feedback: March 20, 2025
End of feedback period: April 3, 2025
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area :
Astrocytoma or oligodendroglioma; IDH1 or IDH2 mutation
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Metastatic castration-sensitive prostate cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Depression
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Attention Deficit Hyperactivity Disorder (ADHD)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Hematology
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Insomnia
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Ulcerative colitis
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Metastatic castration-resistant prostate cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Unresectable or metastatic MSI-H or dMMR colorectal cancer
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :
Therapeutic Area
Therapeutic Area :
Mantle cell lymphoma (MCL)
Call For Patient Input:
Call For Patient Input :
Patient Input Closed
Patient Input Closed :